TKNO — Alpha Teknova, Inc.

Summary of Teknova's Q4 and Full Year 2025 Earnings Call

1. Key Financial Results and Metrics:

• Revenue Growth: Q4 2025 revenue was $10.0 million, an 8% increase year-over-year, with full-year revenue at $40.5 million, up 7% from 2024.
• Gross Profit: Q4 gross profit was $3.2 million (32.5% margin), compared to $2.1 million (23.0% margin) in Q4 2024. Full-year gross profit was $13.4 million (33.2% margin), up from $7.2 million (19.2% margin) in 2024.
• Net Loss: Q4 net loss was $4.8 million ($0.09 per share), improved from a loss of $5.7 million ($0.11 per share) in Q4 2024. Full-year net loss was $17.3 million ($0.32 per share), down from $26.7 million ($0.57 per share) in 2024.
• Adjusted EBITDA: Q4 adjusted EBITDA was negative $1.8 million, improving from negative $3.2 million in Q4 2024. Full-year adjusted EBITDA was negative $6.7 million, a significant improvement from negative $14.5 million in 2024.
• Free Cash Flow: Full-year free cash flow was negative $9.8 million, better than the guidance of less than $12 million.

2. Strategic Updates and Business Highlights:

• Customer Growth: The number of active clinical customers increased to 60, a 25% rise from 2024, supporting 70 therapies, with 5 in Phase II or later.
• Product Segments: Catalog products drove low double-digit growth, while Clinical Solutions revenue increased by 47% in Q4, attributed to more customers.
• Operational Efficiency: Achieved approximately 95% on-time delivery and improved gross margins due to efficiency gains.
• Investment in Growth: Plans to invest an additional $2 million in commercial capabilities to enhance market presence and accelerate revenue growth, particularly in sequencing, spatial genomics, and cancer screening.

3. Forward Guidance and Outlook:

• 2026 Revenue Guidance: Expected total revenue of $42 million to $44 million, implying approximately 6% growth compared to 2025.
• Long-term Growth Target: Positioned for sustainable revenue growth of 20% to 25% over the longer term, with expectations to achieve adjusted EBITDA positivity by the end of 2027.
• Market Conditions: Anticipated growth in biopharma-related revenue beginning in Q4 2026, contingent on continued biotech funding and FDA approvals for supported therapies.

4. Bad News, Challenges, or Points of Concern:

• Declining Average Revenue per Customer: Average revenue per customer decreased by 14% in 2025, attributed to the addition of new customers with lower initial order volumes.
• Market Recovery Uncertainty: While there are signs of increased biotech funding, the company remains cautious about a sustained recovery in the sector, which could impact revenue growth.
• Operational Risks: High fixed costs associated with operations may lead to variability in quarterly results, and the timing of revenue recognition is subject to customer trial phases.

5. Notable Q&A Insights:

• Emerging Market Segments: Management discussed the potential for growth in sequencing and cancer screening, emphasizing the importance of commercial investments to capture larger orders.
• Customer Transition: The average revenue step-up for customers transitioning from RUO to GMP is significant, with potential increases of 30-fold upon commercialization of therapies.
• Biotech Funding Impact: Management indicated a 4-quarter lag between biotech funding changes and revenue impact, with custom biopharma products being the most affected segment.
• FDA Guidance: Shortening drug development timelines could positively impact Teknova's business, particularly as customers move towards commercialization more quickly.

Overall, Teknova demonstrated solid financial performance in 2025, with strategic initiatives aimed at enhancing growth potential, despite facing challenges related to customer revenue dynamics and market recovery uncertainties.